Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL)

Peters, 2014, Targeted therapy in NSCLC driven by HER2 insertions, Transl Lung Cancer Res, 3, 84 Kris, 2014, Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs, JAMA, 311, 1998, 10.1001/jama.2014.3741 Mazieres, 2013, Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives, J Clin Oncol, 31, 1997, 10.1200/JCO.2012.45.6095 Arcila, 2012, Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas, Clin Cancer Res, 18, 4910, 10.1158/1078-0432.CCR-12-0912 Shigematsu, 2005, Somatic mutations of the HER2 kinase domain in lung adenocarcinomas, Cancer Res, 65, 1642, 10.1158/0008-5472.CAN-04-4235 Jebbink, 2020, The force of HER2 - a druggable target in NSCLC?, Cancer Treat Rev, 86, 10.1016/j.ctrv.2020.101996 Zhou, 2020, Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies, Ther Adv Med Oncol, 12, 10.1177/1758835920936090 Auliac, 2019, Non-small cell lung cancer patients harboring HER2 mutations: clinical characteristics and management in a real-Life setting. Cohort HER2 EXPLORE GFPC 02-14, Adv Ther, 36, 2161, 10.1007/s12325-019-01001-9 Lai, 2019, Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study, Eur J Cancer, 109, 28, 10.1016/j.ejca.2018.11.030 Socinski, 2020, LBA60 ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations, Ann Oncol, 31, S1188, 10.1016/j.annonc.2020.08.2293 Smit, 2021, MA11.03 trastuzumab deruxtecan in HER2-mutated metastatic Non-Small Cell Lung Cancer (NSCLC): interim results of DESTINY-lung01, J Thorac Oncol, 16, S173, 10.1016/j.jtho.2021.01.248 Nakagawa, 2021, OA04.05 trastuzumab deruxtecan in HER2-overexpressing metastatic Non-Small Cell Lung Cancer: interim results of DESTINY-lung01, J Thorac Oncol, 16, S109, 10.1016/j.jtho.2021.01.285 Wang, 2019, HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib, Ann Oncol, 30, 447, 10.1093/annonc/mdy542 Zhou, 2020, Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase II study, J Clin Oncol, 38, 2753, 10.1200/JCO.20.00297 Zhang, 2020, Next-generation sequencing (NGS) identifies a new breast cancer subtype with HER2 low-amplification status as a candidate for targeted therapy, J Clin Oncol, 38, 553, 10.1200/JCO.2020.38.15_suppl.553 Dziadziuszko, 2019, Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP), J Thorac Oncol, 14, 1086, 10.1016/j.jtho.2019.02.017 Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189-194. https://doi.org/10.1038/nature25475. Kris, 2015, Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors, Ann Oncol, 26, 1421, 10.1093/annonc/mdv186 Robichaux, 2019, Pan-cancer landscape and analysis of ERBB2 mutations identifies Poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity, Cancer Cell, 36, 444, 10.1016/j.ccell.2019.09.001 Li, 2018, Ado-Trastuzumab Emtansine for patients with HER2-Mutant Lung Cancers: results from a phase II basket trial, J Clin Oncol, 36, 2532, 10.1200/JCO.2018.77.9777 Fang, 2020, Mutation variants and co-mutations as Genomic modifiers of response to Afatinib in HER2-Mutant Lung Adenocarcinoma, Oncologist, 25, e545, 10.1634/theoncologist.2019-0547 Zhao, 2020, Conformational landscapes of HER2 Exon 20 insertions explain their sensitivity to Kinase inhibitors in Lung Adenocarcinoma, J Thorac Oncol, 15, 962, 10.1016/j.jtho.2020.01.020 Chen, 2020, Effectiveness and safety of Pyrotinib, and association of biomarker with progression-free survival in patients with HER2-positive metastatic Breast Cancer: a real-world, multicentre analysis, Front Oncol, 10, 811, 10.3389/fonc.2020.00811